FIA
ESPR

Foundations Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Foundations Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,000
Closed -$110K – 1236
2026
Q1 		$110K Sell
40,000
-108
-0.3% -$342 ﹤0.01% 1140
2025
Q4 		$148K Sell
40,108
-49
-0.1% -$158 ﹤0.01% 1081
2025
Q3 		$106K Sell
40,157
-10,000
-20% -$19.3K ﹤0.01% 1022
2025
Q2 		$49.4K Sell
50,157
-15
-0% -$15 ﹤0.01% 907
2025
Q1 		$72.2K Buy
50,172
+20,000
+66% +$36.9K ﹤0.01% 832
2024
Q4 		$66.4K Buy
30,172
+9,872
+49% +$23K ﹤0.01% 823
2024
Q3 		$33.5K Buy
20,300
+300
+2% +$606 ﹤0.01% 805
2024
Q2 		$44.4K Hold
20,000
– – ﹤0.01% 741
2024
Q1 		$53.6K Hold
20,000
– – ﹤0.01% 696
2023
Q4 		$41.4K Buy
+20,000
New +$25.9K ﹤0.01% 659

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Foundations Investment Advisors's ESPR Position: Q2 2026 in Review

Foundations Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 40,000 shares — an estimated $110K sold.

Foundations Investment Advisors first reported a position in ESPR in Q4 2023 and held it in 10 quarters. The position peaked at $148K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Foundations Investment Advisors reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Foundations Investment Advisors sold 40,000 Esperion Therapeutics shares in Q2 2026, an estimated $110K.
  • Foundations Investment Advisors first reported a position in Esperion Therapeutics in Q4 2023 and held it in 10 quarters.
  • Foundations Investment Advisors's Esperion Therapeutics position peaked at $148K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Foundations Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.